Regeneron's combo plan for obesity drug Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 2 October, 2026

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

news Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront Regeneron sees a future combining its obesity drug with lipid-lowering therapy Peer Review Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board News Briefing Nektar stock tumbles on long-term alopecia data; Mabwell's T cell engager subsidiary

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

ENDPOINTS AT #EASD26 Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy Boehringer's weight loss candidate trails rivals in diabetes and obesity Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes Zealand and Roche's amylin works best at middle dose, trails Lilly's Lilly's triple-G allows more than half of patients to drop below obesity line